You are here
Senior Vice President and Medicine Team Leader, Pfizer
Kenneth Verburg, Ph.D., has nearly 25 years of experience in the development and registration of new medicines for acute and chronic pain which includes Celebrex, Dynastat, and Lyrica. Dr. Verburg is currently responsible for the late-stage clinical development of tanezumab, a monoclonal antibody targeting nerve growth factor, for the management of chronic pain.
During his 16-year tenure with Pfizer, Dr. Verburg has also held the positions of Chief Development Officer for Neuroscience and Pain, Head of the Medicines Development Group for the Global Innovative Pharma Business, Development Leader for Pain Therapeutics, and the Development Leader for Inflammation & Immunology.
Dr. Verburg joined Pfizer from Pharmacia in 2003 where he held various positions with Searle (then Pharmacia) culminating in the job of Clinical Vice President for Arthritis, Inflammation, and Pain. Dr. Verburg also spent 2 years in Medical Affairs with Searle supporting cardiovascular and sedative/hypnotic medications, 4 years as a Director of Product Development focused on dermatologic and topical analgesics for GenDerm Corp, and 5 years as a cardiorenal research pharmacologist with Abbott Laboratories.
This page last reviewed on May 17, 2019